Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bruckner HG, Cohen CJ, Wallach RC, Kabakow B, Deppe G, Greenspan EM, Gusberg SB, Holland JF (1978) Treatment of advanced ovarian cancer with cis-dichlorodiammineplatinum (II): Poor risk patients with intensive prior therapy. Cancer Treat Rep 62:555
Bruno S, Poster DS, Higby DJ, Burke P, Mittelman A (1980) Parameters of nephrotoxicity in relation to the administration of cis-DPD. Proc Am Assoc Cancer Res 21:150
Chantler C, Garnett ES, Parsons V, et al. (1969) Glomerular filtration rate measurement in man by the single injection methods using Cr51 EDTA. Clin Sci Mol Med 37:169
Harrap KR (to be published) Platinum analogues: Criteria for selection: In: Muggia FM (ed) Cancer chemotherapy. Martinus Nijhoff, Massachusetts
Harrap KR, Jones M, Wilkinson CR, Clink HMcD, Sparrow S, Mitchley BCV, Clarke SA, Veasy A (1980) Antitumour, toxic and biochemical properties of cisplatin and eight other platinum complexes. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin. Current status and new developments. Academic Press, New York, p 193
Hayes DM Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH (1980) High-dose cis-platinum diamminedichloride. Cancer 39:1372
Herr HW (1980) cis-Diamminedichloride platinum II in the treatment of advanced bladder cancer. J Urol 123:853
Higby DJ, Wallace HJ Jr, Alberts D, Holland JF (1971) Diamminodichloroplatinum in the chemotherapy of testicular tumors. J Urol 112:100
Jacobs C (1980) The role of cisplatin in the treatment of recurrent head and neck cancer: In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin. Current status and new developments. Academic Press, New York, p 423
Jones BR, Bhalla RB, Mladek J, Kaleya RN, Gralla RJ, Alcock NW, Schwartz MK, Young CW, Reidenberg MM (1980) Comparison of methods of evaluating nephrotoxicity of cisplatinum. Clin Pharmacol Ther 27:557
Loo TL, Hall SW, Salem P, Benjamin RS, Lu K (1978) Clinical, pharmacological and toxicological studies of cis-diamminedichloroplatinum (II) by continuous infusion. Biochimie 60:957
Merrin C (1978) Treatment of advanced bladder cancer with cis-diamminedichloroplatinum (II) (NSC 119875): A pilot study. J Urol 119:493
Merrin CE (1979) Treatment of genitourinary tumors with cis-dichlorodiammineplatinum (II): Experience in 250 patients. Cancer Treat Rep 63:1579
Prestayko AW, D'Aoust JC, Issell BF, Crooke ST (1979) Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev 6:17
Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersall MHN (1982) Ototoxicity in patients receiving cisplatin: Importance of dose and method of drug administration. Cancer Treat Rep 66:19
Von Hoff DD, Schilsky R, Reichert CB, Reddick RL, Rozencweig M, Young RC, Muggia FM (1979) Toxic effects of cis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep 63:1527
Wilkinson R, Cox PJ, Jones M, Harrap KR (1978) Selection of potential second generation platinum compounds. Biochimie 60:851
Wiltshaw E, Carr T (1974) cis-Platinum(II)diamminedichloride: Clinical experience of the Royal Marsden Hospital and Institute of Cancer Research. Recent Results Cancer Res 48:178
Wiltshaw E, Kroner T (1976) Phase II study of cis-dichloro-diammineplatinum (I) (NSC 119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep 60:55
Witman G, Cadman E, Browerman I (1981) Cisplatin treatment of cutaneous T-cell lymphoma. Cancer Treat Rep 65:920
Yagoda A, Watson RC, Gonzalez-Vitale JC, Grabstald H, Whitmore WF (1976) cis-Dichlorodiammineplatinum (II) in advanced bladder cancer. Cancer Treat Rep 60:917
Young RC, Von Hoff DD, Gormley P, Makuch R, Cassidy J, Howser D, Bull JM (1979) cis-Dichlorodiammineplatinum (II) for the treatment of advanced ovarian cancer. Cancer Treat Rep 63:1539